As a complex, inherited disease, cystic fibrosis impacts the respiratory, gastrointestinal and reproductive systems. Many clinical trials are examining therapies that target this rare disease from different therapeutic angles, such as restoring function to a faulty protein, reducing inflammation, clearing mucus buildup, addressing gastrointestinal manifestations or fighting cystic fibrosis-related infections.Continue reading
LabCorp was recently recognized as one of the “Best Places to Work for LGBTQ Equality” by the Human Rights Campaign Foundation with a score of 100% on the Corporate Equality Index. To learn more about what workplace equality means at Covance, we recently spoke with a few leaders of the Pride Network and heard how the group supports LGBTQ employees and allies across the organization.Continue reading
Amics Therapeutics, based in Cranbury, NJ (USA), focuses on finding treatments for a range of devastating and rare and orphan diseases. Its lead biologics program is ATB200/AT2221, a uniquely engineered Pompe disease enzyme replacement therapy that will be administered in combination with a pharmacological chaperone and tested in multiple human genetic diseases.Continue reading
Clinical research associates (CRAs) need immediate access to relevant and accurate site performance metrics, but information is often isolated within multiple databases and spread across different tracking systems. To deliver key site performance data to CRAs via mobile and web applications – quickly and conveniently – Covance has created a specialized clinical analytics suite of products, Covance Xcellerate® Informatics. This powerful solution integrates data from all sources and allows a CRA to gain a clear and concise view of all clinical trial data, in one place, for all the sites that a CRA is monitoring.
Is it possible for a global CRO to improve – and even reshape – today’s drug development industry? We think so. We work with people like you to offer unique perspectives at every stage of development – from early phase development to clinical trials and commercialization.
But enough about us.
In order to ensure you receive the information you are most interested in, we’ve recently launched a Preference Center to ensure we only send you content that matters to you. Take a minute and complete your profile today.